NeoGenomics (NEO) reported Tuesday Q4 adjusted earnings of $0.04 per diluted share, up from $0.03 a year earlier.
Analysts polled by FactSet expected $0.03.
Net revenue for the quarter ended Dec. 31 was $172 million, up from $155.6 million a year earlier.
Analysts surveyed by FactSet expected $173.2 million.
For 2025, the company expects adjusted diluted EPS of $0.15 to $0.19. Analysts surveyed by FactSet expect $0.20.
The company expects 2025 consolidated revenue of $735 million to $745 million. Analysts polled by FactSet expect $733.1 million.
Shares were down nearly 8% in premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。